An implant for eye disease for controlling intraocular pressure, the implant including a coating layer formed on the outside of an implant substrate. Specifically, the present invention relates to an implant that may suppress a foreign body reaction from occurring around the implant, because the implant includes a coating layer, which is formed on the outside of an implant substrate and is a cured product of a polymer of a composition containing an acrylate-based monomer and a (meth)acryloyloxyethyl phosphorylcholine monomer.

Disclosed are co-polymers which are produced from reactive monomer mixtures and which have both high refractive index and a high Abbe number. These materials are well suited for use as implantable ophthalmic devices and have a refractive index which may be edited through application of energy. When used for an intraocular lens, the high refractive index allows for a thin lens which compresses to allow a small incision size.

Thin parylene C membranes having smooth front sides and ultrathin regions (e.g., 0.01 μm to 5 μm thick) interspersed with thicker regions are disclosed. The back sides of the membranes can be rough compared with the smooth front sides. The membranes can be used in vitro to grow monolayers of cells in a laboratory or in vivo as surgically implantable growth layers, such as to replace the Bruch's membrane in the eye. The thin regions of parylene are semipermeable to allow for proteins in serum to pass through, and the thick regions give mechanical support for handling by a surgeon. The smooth front side allows for monolayer cell growth, and the rough back side helps prevents cells from attaching there.

The present invention relates to a material for preparing an intraocular lens. In particular, it relates to an ophthalmic medical material suitable for manufacture of micro-incision intraocular lens, having suitable water content and a suitable refractive index.

The invention relates to an aqueous viscoelastic solution comprising: at least one polymer selected from among hyaluronic acid and the salts thereof, and cellulosic derivatives and the salts thereof, in particular hydroxypropyl methylcellulose and the salts thereof; and at least one water-soluble polymer of the polyether-polyurethane or polyether-polyester-urethane type, and to the use thereof in a device intended for the injection of an intraocular implant.

Disclosed are adjustable accommodating intraocular lenses and methods of adjusting accommodating intraocular lenses post-operatively. In one embodiment, an adjustable accommodating intraocular lens comprises an optic portion and a peripheral portion. At least one of the optic portion and the peripheral portion can be made in part of a composite material comprising an energy absorbing constituent and a plurality of expandable components. At least one of a base power and a cylindricity of the optic portion can be configured to change in response to an external energy directed at the composite material.

Described herein are devices used to treat high intraocular pressure and glaucoma. An example device includes a plate comprising a first surface opposite a second surface. The first surface includes a series of fluid channels. The device also includes a first coating on the first surface and a second coating on the second surface. The device is configured to lower intraocular pressure by draining aqueous humor from an anterior chamber to subconjunctival space of a patient's eye.

Various aspects and embodiments of the present invention are directed to methods of treating a subject having an ocular condition, methods of isolating ocular stem cells, methods of selecting and/or producing ocular grafts for transplantation, and methods of promoting ocular cell regeneration as well as to grafts and preparations containing isolated ocular stem cells characterized by the expression of ABCB5 on their cell surface.

In one aspect, the disclosure relates pertains to a vitreous substitute comprising a gel and an antioxidant, wherein the vitreous substitute mimics the physical properties of natural vitreous humor, as well as its methods of use in the treatment of ophthalmological disorders.

Methods and compositions for reducing the activity or number of memory Th17 cells in ocular tissue, and for treatment and/or prevention of ocular immunoinflammatory diseases are described.